The 50 most recent market catalysts affecting $AZN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Maintains 'Buy' Rating on AstraZeneca
Jefferies, a prominent analyst firm, reaffirmed its 'Buy' rating on AstraZeneca, a significant pharmaceutical company, following an internal industry conference. The key takeaway f…
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Receives US and EU Approval for Klygefa
AstraZeneca has secured crucial regulatory approvals for Klygefa in both the United States and the European Union, a major milestone for the company. This drug, indicated for myast…
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 65
AstraZeneca Announces US Workforce Reduction
AstraZeneca announced a reduction of 600 US sales positions, effective November 13, 2026, as part of a broader cost-cutting program. This action indicates the company's strategic e…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca's Baxfendy Wins Positive EMA Recommendation for Hypertension
AstraZeneca's hypertension drug, Baxfendy, has received a positive recommendation from the European Medicines Agency (EMA), a crucial step towards its approval in the European Unio…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 55
AstraZeneca Achieves 100% Requisition Coverage with AI Alignment Agent
AstraZeneca announced the successful deployment of an AI-powered Alignment Agent, developed in collaboration with Pactum, to automate and optimize its procurement processes. This i…
Nov 10, 2026
Corporate Catalyst
Neutral
Impact 55
AstraZeneca Advances Digital Transformation with SAP Cloud ERP
AstraZeneca is undertaking a significant digital transformation by migrating its legacy SAP ERP systems to SAP Cloud ERP Private. This initiative, part of its Axial Business Transf…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca Acquires Preclinical Biotech Firm Omniose
AstraZeneca's acquisition of Omniose, a preclinical biotech firm, is a strategic move to bolster its Infectious Disease Unit. This integration of Omniose's proprietary bioconjugati…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 55
AstraZeneca and Barcelona Supercomputing Centre Sign AI and Supercomputing Agreement
AstraZeneca and the Barcelona Supercomputing Centre have signed a formal agreement to collaborate on AI and supercomputing research. This partnership is significant as it aims to l…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
Bernstein Upgrades AstraZeneca Price Target and Reaffirms Outperform Rating
Investment firm Bernstein has raised its price target for AstraZeneca PLC and reaffirmed its 'Outperform' rating. This action signals continued positive analyst sentiment towards t…
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 55
AlphaValue/Baader Europe Downgrades AstraZeneca to Reduce
AlphaValue/Baader Europe, a financial research firm, has lowered its investment rating on AstraZeneca from 'Add' to 'Reduce'. This downgrade, reported on November 2, 2026, signals …
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Raises Price Target on AstraZeneca
RBC Capital Markets has raised its price target for AstraZeneca PLC to GBP 152.50 from GBP 145.00, while reiterating its 'Outperform' rating. This adjustment reflects RBC's updated…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Reports Q3 2026 Financial Results
AstraZeneca's Q3 2026 earnings report indicates strong financial health with growth in both profit and revenue, primarily fueled by its oncology segment and products like Imfinzi. …
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca and Daiichi Sankyo's Enhertu Approved in EU for HER2-positive Early Breast Cancer
AstraZeneca and Daiichi Sankyo announced EU approval for their drug Enhertu as an adjuvant treatment for HER2-positive early breast cancer in patients with residual disease after n…
Oct 27, 2026
Corporate Catalyst
Neutral
Impact 65
AstraZeneca Updates PACIFIC-9 Phase 3 Trial Data Readout Timeline
AstraZeneca announced a delay in the high-level data readout for its PACIFIC-9 Phase 3 trial, moving it from the second half of 2026 to the first half of 2027. This trial is evalua…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 85
AstraZeneca Imfinzi Demonstrates Significant Survival Benefits in Lung and Bladder Cancer Studies
AstraZeneca presented compelling clinical data at ESMO 2026, showing Imfinzi significantly reduced the risk of death in lung and bladder cancer patients. This is a major positive d…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca and HUTCHMED Present Positive Phase III Data for Lung Cancer Combination Therapy
AstraZeneca and HUTCHMED announced positive Phase III clinical trial results for their combination therapy, ORPATHYS and TAGRISSO, for first-line EGFR-mutated non-small cell lung c…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca and Daiichi Sankyo Receive Conditional Approval for Enhertu in China
AstraZeneca and Daiichi Sankyo have secured conditional approval in China for a new indication of their cancer therapy, Enhertu. This regulatory milestone is significant as it broa…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Reports Positive Clinical Trial Results for New Drug
AstraZeneca reported successful 52-week clinical trial results for a new therapeutic candidate, showing statistically significant efficacy in achieving complete endoscopic remissio…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca Announces US Availability of ZEGFROVY for NSCLC
AstraZeneca has announced the U.S. availability of ZEGFROVY (sunvozertinib), a new treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGF…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
AstraZeneca Enters Partnership with Abu Dhabi Biobank for Predictive Healthcare
AstraZeneca has entered a strategic partnership with the Abu Dhabi Biobank to advance predictive healthcare. This collaboration is significant as it leverages data and research cap…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca's Ultomiris Receives FDA Accelerated Approval for IgA Nephropathy
AstraZeneca's Alexion unit secured accelerated FDA approval for Ultomiris (ravulizumab-cwvz) to treat proteinuria in adult IgA nephropathy patients at risk of disease progression. …
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca shares are trading higher after the company and Amgen reported that TEZSPIRE demonstrated meaning improvements in histologic remission and dysphagia in a Phase 3 CROSSING trial for eosinophilic esophagitis.
The positive Phase 3 trial results for TEZSPIRE in eosinophilic esophagitis represent a significant corporate catalyst for AstraZeneca and Amgen. This expands the potential market …
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
AstraZeneca and Amgen reported full positive results from their Phase 3 CROSSING trial for Tezspire in treating eosinophilic esophagitis (EoE). The drug met co-primary endpoints, s…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
AstraZeneca and Amgen announced that their co-developed drug, TEZSPIRE, met its co-primary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis (EoE). This is sig…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca To Present 100+ Cancer Research Abstracts, Including Five Phase III Trials, At ESMO 2026
AstraZeneca is announcing its upcoming presentations at the ESMO 2026 Congress, detailing over 100 abstracts, including five pivotal Phase III trials. This matters because positive…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca (AZN) announced a significant collaboration with Insitro, an AI-driven drug developer, to target challenging cardiometabolic diseases like MASH and cardiomyopathies. Th…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Entered Strategic Drug Discovery Collaboration, Licensing Agreement With Insitro To Use Advanced AI Systems To Identify Novel Drug Targets, Develop Therapeutics For MASH, Cardiomyopathies
This strategic collaboration between AstraZeneca and Insitro is a significant corporate catalyst, highlighting the increasing integration of advanced AI in pharmaceutical R&D. For …
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Trial Goal
AstraZeneca announced detailed results from its HICKORY Phase 3 trial for efzimfotase alfa in hypophosphatasia (HPP). While the drug initially missed its primary endpoint (Six-Minu…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 65
AstraZeneca Announces The Opening Of Its Newest Global Strategic Research And Development Center, In Kendall Square, Cambridge, Massachusetts; Co. invests $1B To Grow Massachusetts Workforce By Over 50%
AstraZeneca has opened a new $1 billion R&D center in Kendall Square, Cambridge, Massachusetts, significantly expanding its footprint and workforce in a major biotech hub. This mov…
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca's IMFINZI-EV Combo For Muscle-Invasive Bladder Cancer Granted FDA Priority Review; PDUFA Decision Expected Q4 2026
AstraZeneca announced that its supplemental Biologics License Application (sBLA) for IMFINZI in combination with enfortumab vedotin (EV) has been granted Priority Review by the FDA…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 75
Transcript: AstraZeneca Q2 2026 Earnings Conference Call
AstraZeneca's Q2 2026 earnings call transcript reveals a 6% increase in total revenue for the first half of 2026, or 11% excluding generic impacts on Farxiga and Brilinta. This ind…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 55
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury
The headline primarily serves as a signal for individual stock interest, driven by recommendations from a popular financial show. While not a fundamental market driver, such mentio…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is AstraZeneca Stock Trading Higher Today?
AstraZeneca's latest clinical updates present a nuanced picture for investors. The eight-year follow-up data for Tagrisso in early-stage lung cancer, showing a significant reductio…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%
AstraZeneca reported groundbreaking Phase III trial results for its drug Tagrisso, demonstrating a 48% reduction in the risk of death compared to placebo in patients with Stage IB-…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial
AstraZeneca and Daiichi Sankyo announced highly positive Phase III trial results for their HER2-directed therapy, Enhertu. The drug demonstrated a 37% reduction in the risk of dise…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment
AstraZeneca announced a trifecta of positive news: accelerated FDA approval for Etcamah in breast cancer, strong Phase 3 data for a lung cancer combination therapy (with Amgen's Im…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer
This headline represents a significant positive catalyst for both AstraZeneca and Amgen. The successful interim analysis of the DeLLphi-305 trial, showing statistically significant…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Announces Tozorakimab Demonstrates Reduction In Participants With Chronic Obstructive Pulmonary Disease In Phase III OBERON, TITANIA Studies
AstraZeneca reported positive Phase III results for Tozorakimab in COPD, showing a statistically significant reduction in exacerbations. This is a crucial development as it validat…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Announces Completion Of Exclusive License Agreement With Dizal Pharmaceutical For Worldwide Rights To ZEGFROVY For $600M Upfront, Up To $900M In Milestones, Plus Tiered Royalties; US Launch Planned Q4 2026
This headline represents a significant corporate catalyst within the pharmaceutical sector. AstraZeneca's acquisition of ZEGFROVY, a potential blockbuster in lung cancer, strengthe…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca and Amgen reported strong Phase 3 results for Tezspire in treating Eosinophilic Esophagitis (EoE), a debilitating swallowing disease. This is significant because it ope…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
AstraZeneca and Amgen reported positive high-level results from the Phase III CROSSING trial for TEZSPIRE in eosinophilic esophagitis (EoE). The drug met both co-primary and all ke…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 65
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
AstraZeneca reported a mixed bag of clinical trial results for its lung cancer treatments. The SAFFRON Phase 3 study for Tagrisso and Orpathys, and the DESTINY-Lung04 Phase 3 trial…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
AstraZeneca And Daiichi Sankyo Report DESTINY‑Lung04 Phase III Trial Results; ENHERTU Improves Progression‑Free Survival Versus Standard Of Care In HER2‑Mutant NSCLC
AstraZeneca and Daiichi Sankyo reported positive high-level results from their DESTINY-Lung04 Phase III trial for ENHERTU, demonstrating a statistically significant and clinically …
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial
AstraZeneca and HUTCHMED reported positive Phase III SAFFRON trial results for their savolitinib and TAGRISSO combination in EGFRm NSCLC patients with MET overexpression/amplificat…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca shares are trading higher after reports suggesting that the company didn't have any merger discussions with Bristol Myers Squibb.
The headline suggests that the market is reacting positively to the absence of merger discussions between AstraZeneca and Bristol Myers Squibb. This removes a significant overhang …
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger
This filing discusses Jim Cramer's skepticism about a potential $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, despite reports from the Financial Times. The…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 65
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
The filing details pre-market declines for several prominent stocks, each with specific drivers. AstraZeneca's reported merger talks with Bristol Myers Squibb, while potentially tr…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 95
AstraZeneca shares are trading lower following reports suggesting the company is in discussions with Bristol Myers Squibb to merge.
A potential merger between AstraZeneca and Bristol Myers Squibb would be a major corporate catalyst, reshaping the pharmaceutical landscape. For AstraZeneca, the 'lower trading' su…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.